Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG103 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
NCT06235086Phase 3Completed
- Sponsor
- CSPC Baike Biopharmaceutical
- Start
- Apr 2024
- Primary completion
- Feb 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of GX-G6 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by CSPC Baike Biopharmaceutical. Primary endpoint: Changes in glycosylated hemoglobin (HbA1c) from baseline at 28 weeks. Started Apr 2024; status: completed.
02
Drugs
GX-G6
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06235086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06235086.